Close Menu
Home » GenMark Diagnostics Downgraded by JP Morgan to Neutral

GenMark Diagnostics Downgraded by JP Morgan to Neutral

Dec 11, 2019
|
staff reporter

NEW YORK – JP Morgan said Wednesday that it has downgraded GenMark Diagnostics' stock to Neutral from Overweight and lowered the molecular diagnostic firm's December 2020 stock price target to $7 from $11.

The investment bank said Carlsbad, California-based GenMark experienced healthy momentum this year in placements of its ePlex molecular diagnostic analyzers, but reimbursement and competitive pressures pose a risk to its business outlook.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

If They Don't Know...

Bloomberg Law writes that the Genetic Information Nondiscrimination Act may work better as a privacy, rather than anti-discrimination, law.

New Startup from Avey

TechCrunch reports that Linda Avey has a new personal genomics startup that's focusing on India.

No Longer 'Uncontested'

A new report finds that though the US has increased its activity in science and engineering, its global share of that activity has fallen in some areas, according to Inside Higher Ed.

Nature Papers Include Analysis of Rapeseed Genome, Target Enrichment Method for Metagenomics

In Nature this week: genomic analysis of rapeseed, universal target enrichment method for metagenomic sequencing, and more.

What's Popular?

In Business News

  1. JP Morgan Healthcare Day One: Qiagen, Guardant Health, Bio-Rad, Hologic, Myriad Genetics

  2. JP Morgan Healthcare Day 2: 10x Genomics, GenapSys, Caris, Adaptive Bio, Danaher, Agilent, Luminex

  3. JP Morgan Healthcare Day 3: Exact Sciences, NanoString, Natera, Horizon, Accelerate Dx, GenMark, More

  4. Judge Dismisses Lawsuit Accusing Illumina, Affymetrix of Fraud, Theft of Trade Secrets

  5. Illumina Unveils New Sequencers; Preliminary Q4 Revenues up 10 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.